[Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure]

Gan To Kagaku Ryoho. 2002 Mar;29(3):435-8.
[Article in Japanese]

Abstract

We administered chemotherapy in three cases of small-cell lung cancer (SCLC) with renal failure under different situations. Hemodialysis (HD) was used in 2 out of the 3 cases. Case 1 was complicated by acute renal failure from extensive bilateral tumor invasion. After chemotherapy (CBDCA + ETP) under HD, renal metastases regressed and renal function improved, although the final response was PD. In case 2, HD had been introduced for diabetic nephropathy. After 2 cycles of chemotherapy (CBDCA + ETP) under HD, the patient attained a PR. Case 3 is an example of paraneoplastic nephrotic syndrome with renal failure. Chemotherapy including CBDCA or CDDP was performed and the QOL of the patient improved. Pro-GRP and serum creatinine changed in parallel during the clinical course of 6 admissions. In conclusion, individualized therapy is necessary to increase survival time of SCLC patients with renal failure. Although chemotherapy is useful, further study is needed for the selection of suitable chemotherapeutic regimens, optimal dosage of each drug and the timing of HD.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carboplatin / pharmacokinetics
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / secondary
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Etoposide / pharmacokinetics
  • Humans
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / secondary
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Paraneoplastic Polyneuropathy / drug therapy*
  • Renal Dialysis
  • Renal Insufficiency / complications*
  • Renal Insufficiency / therapy

Substances

  • Etoposide
  • Carboplatin